Truelove S C, Rocca M
Curr Med Res Opin. 1976;4(3):218-22. doi: 10.1185/03007997609109307.
A long-term controlled therapeutic trial of gefarnate (600 mg daily) in the treatment of chronic gastric ulcer was carried out in 32 patients. Assessment was based on the clinical course and on repeated radiological and endoscopic examinations, which were performed after 3-months' treatment, at the end of the 1-year trial period, and towards the end of a follow-up period of approximately 2 1/2 to 3 1/2 years. In men with gastric ulcer, gefarnate proved to be highly effective, with 10 out of the 11 patients who received this treatment showing persistent healing of the ulcer compared with only 4 out of the 11 who were on dummy treatment. In the very small group of women it was not possible to show any difference between treatments. No adverse reactions to gefarnate occurred. These results suggest that gefarnate is a safe and effective treatment for chronic gastric ulcer.
对32例慢性胃溃疡患者进行了一项关于吉法酯（每日600毫克）的长期对照治疗试验。评估基于临床病程以及在治疗3个月后、1年试验期结束时和大约2年半至3年半随访期结束时进行的反复放射学和内镜检查。在患有胃溃疡的男性中，吉法酯被证明非常有效，接受该治疗的11例患者中有10例溃疡持续愈合，而接受安慰剂治疗的11例患者中只有4例溃疡愈合。在非常小的女性组中，无法显示出治疗之间的任何差异。未发生对吉法酯的不良反应。这些结果表明，吉法酯是治疗慢性胃溃疡的一种安全有效的药物。
